The BIN3 Knockout SK-HEP-1 Polyclonal Cells product from Ascent Research provides a CRISPR/Cas9-mediated gene-disrupted cell population targeting BIN3 in the human SK-HEP-1 liver adenocarcinoma cell line. This polyclonal knockout pool is designed to enable loss-of-function studies without clonal isolation, offering a heterogeneous population representative of diverse editing events. The product facilitates robust investigation of BIN3-dependent cellular processes in a cancer-relevant context.
SK-HEP-1 is a widely used hepatocellular carcinoma cell line originally derived from the ascitic fluid of a 52-year-old male patient with liver adenocarcinoma. The cells exhibit a mixed phenotype with both endothelial and epithelial characteristics, making them particularly valuable for studies of tumor cell plasticity, metastasis, and angiogenesis. Their adherent growth and reproducible behavior in standard culture conditions support a broad range of functional assays.
BIN3 encodes a BAR domain-containing adapter protein that plays a critical role in integrin internalization, endocytosis, and autophagy. Mechanistically, BIN3 interacts with integrin beta subunits such as ITGB1 and ITGB3, as well as ARF GTPases, dynamin, BIN1, and AMPH. Upstream signals from integrins (ITGA5/ITGB1), growth factors including EGF and HGF, and Rho GTPases (Rac1, Cdc42) converge on BIN3 to regulate focal adhesion dynamics. Downstream, BIN3 modulates key effectors including FAK (PTK2), Src kinase, actin polymerization, and autophagosome formation, thereby controlling cell adhesion, migration, and degradation pathways.
In SK-HEP-1 cells, loss of BIN3 function disrupts integrin recycling and attenuates FAK/Src signaling, leading to altered focal adhesion turnover and reduced cell motility. This perturbation is expected to impact hepatocellular carcinoma cell invasion and metastatic potential, making the knockout model highly relevant for studying tumor progression mechanisms. Additionally, BIN3??s role in autophagy may be interrogated in this context, providing insights into how cancer cells balance survival and death signals.
Researchers can employ this polyclonal BIN3 knockout SK-HEP-1 model in a variety of applications, including investigation of integrin trafficking dynamics, screening for anti-metastatic compounds, and elucidation of autophagy regulation in liver cancer. Representative assays that can be performed with these cells include Western blotting for BIN3, ITGB1, total and phosphorylated FAK; immunofluorescence to assess integrin localization; Transwell migration and invasion assays; cell adhesion assays; co-immunoprecipitation to probe BIN3?Cintegrin interactions; flow cytometry to measure integrin surface levels; and transcriptomic analysis by RNA-seq. For further information or to request a quote, please contact Ascent Research.
